In vitro activity of geldanamycin derivatives against schistosoma japonicum and brugia malayi

Journal of Parasitology Research

Volumn 2010, Issue , 2010, Pages

  Wenkert, David ^a   Ramirez, Bernadette ^b,c   Shen, Yuehai ^a   Kron, Michael A ^d  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5' BROMOGELDANOXAZINONE; ALBENDAZOLE; ALVESPIMYCIN; GELDANAMYCIN; HEAT SHOCK PROTEIN 90 INHIBITOR; TANESPIMYCIN; UNCLASSIFIED DRUG;

ANTHELMINTIC ACTIVITY; ARTICLE; BRUGIA MALAYI; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; SCHISTOSOMA JAPONICUM;

BRUGIA MALAYI; SCHISTOSOMA JAPONICUM;

EID: 79955413031     PISSN: 20900023     EISSN: 20900031     Source Type: Journal    
DOI: 10.1155/2010/716498     Document Type: Article

References (36)

1. Pearl L. H., Prodromou C., Structure and mechanism of the Hsp90 molecular chaperone machinery Annual Review of Biochemistry 2006 75 271 294 (Pubitemid 44118034)
2. Zhao R., Houry W. A., Hsp90: a chaperone for protein folding and gene regulation Biochemistry and Cell Biology 2005 83 6 703 710 (Pubitemid 43200408)
3. DeBoer C., Meulman P. A., Wnuk R. J., Peterson D. H., Geldanamycin, a new antibiotic Journal of Antibiotics 1970 23 9 442 447
4. Stebbins C. E., Russo A. A., Schneider C., Rosen N., Hartl F. U., Pavletich N. P., Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent Cell 1997 89 2 239 250 (Pubitemid 27199896)
5. Grenert J. P., Sullivan W. P., Fadden P., Haystead T. A. J., Clark J., Mimnaugh E., Krutzsch H., Ochel H. J., Schulte T. W., Sausville E., Neckers L. M., Toft D. O., The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation Journal of Biological Chemistry 1997 272 38 23843 23850 (Pubitemid 27410964)
6. Banerji U., Judson I., Workman P., The clinical applications of heat shock protein inhibitors in cancerpresent and future Current Cancer Drug Targets 2003 3 5 385 390 (Pubitemid 37128325)
7. Workman P., Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone Cancer Letters 2004 206 2 149 157 (Pubitemid 38317285)
8. David C. L., Smith H. E., Raynes D. A., Pulcini E. J., Whitesell L., Expression of a unique drug-resistant Hsp90 ortholog by the nematode Caenorhabditis elegans Cell Stress and Chaperones 2003 8 1 93 104 (Pubitemid 36444095)
9. Him N. A., Gillan V., Emes R. D., Maitland K., Devaney E., Hsp-90 and the biology of nematodes BMC Evolutionary Biology 2009 9 1, article no. 254
10. Sausville E. A., Tomaszewski J. E., Ivy P., Clinical development of 17-allylamino, 17-demethoxygeldanamycin Current Cancer Drug Targets 2003 3 5 377 383 (Pubitemid 37128324)
11. Heath E. I., Gaskins M., Pitot H. C., Pili R., Tan W., Marschke R., Liu G., Hillman D., Sarkar F., Sheng S., Erlichman C., Ivy P., A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer Clinical Prostate Cancer 2005 4 2 138 141 (Pubitemid 41474610)
12. Ronnen E. A., Kondagunta G. V., Ishill N., Sweeney S. M., DeLuca J. K., Schwartz L., Bacik J., Motzer R. J., A phase II trial of 17-(Allylamino)-17- demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma Investigational New Drugs 2006 24 6 543 546 (Pubitemid 44273031)
13. Ramanathan R. K., Egorin M. J., Eiseman J. L., Ramalingam S., Friedland D., Agarwala S. S., Ivy S. P., Potter D. M., Chatta G., Zuhowski E. G., Stoller R. G., Naret C., Guo J., Belani C. P., Phase I and pharmacodynamic study of 17-(allylamino)-17- demethoxygeldanamycin in adult patients with refractory advanced cancers Clinical Cancer Research 2007 13 6 1769 1774 (Pubitemid 46952944)
14. Bagatell R., Gore L., Egorin M. J., Ho R., Heller G., Boucher N., Zuhowski E. G., Whitlock J. A., Hunger S. P., Narendran A., Katzenstein H. M., Arceci R. J., Boklan J., Herzog C. E., Whitesell L., Ivy S. P., Trippett T. M., Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17- demethoxygeldanamycinin pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study Clinical Cancer Research 2007 13 6 1783 1788 (Pubitemid 46952946)
15. Weigel B. J., Blaney S. M., Reid J. M., Safgren S. L., Bagatell R., Kersey J., Neglia J. P., Ivy S. P., Ingle A. M., Whitesell L., Gilbertson R. J., Krailo M., Ames M., Adamson P. C., A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a children's oncology group study Clinical Cancer Research 2007 13 6 1789 1793 (Pubitemid 46952947)
16. Murgo A. J., Kummar S., Gardner E. R., Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) administered twice weekly Journal of Clinical Oncology 2007 25 3566
17. Schnur R. C., Corman M. L., Tandem [3,3]-sigmatropic rearrangements in an ansamycin: stereospecific conversion of an (S)-allylic alcohol to an (S)-allylic amine derivative Journal of Organic Chemistry 1994 59 9 2581 2584
18. Shen Y., Xie Q., Norberg M., Sausville E., Vande Woude G., Wenkert D., Geldanamycin derivative inhibition of HGF/SF-mediated Met tyrosine kinase receptor-dependent urokinase-plasminogen activation Bioorganic and Medicinal Chemistry 2005 13 16 4960 4971 (Pubitemid 40943520)
19. Rinehart K. L. Jr., McMillan M. W., Witty T. R., Synthesis of phenazine and phenoxazinone derivatives of geldanamycin as potential polymerase inhibitors Bioorganic Chemistry 1977 6 3 353 369 (Pubitemid 8182743)
20. Schnur R. C., Corman M. L., Gallaschun R. J., Cooper B. A., Dee M. F., Doty J. L., Muzzi M. L., DiOrio C. I., Barbacci E. G., Miller P. E., Pollack V. A., Savage D. M., Sloan D. E., Pustilnik L. R., Moyer J. D., Moyer M. P., erbB-2 oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action, and structure-activity relationships Journal of Medicinal Chemistry 1995 38 19 3813 3820
21. Chen B., Zhong D., Monteiro A., Comparative genomics and evolution of the HSP90 family of genes across all kingdoms of organisms BMC Genomics 2006 7, article no. 156
22. Chne P., ATPases as drug targets: learning from their structure Nature Reviews Drug Discovery 2002 1 9 665 673
23. Devaney E., O'Neill K., Harnett W., Whitesell L., Kinnaird J. H., Hsp90 is essential in the filarial nematode Brugia pahangi International Journal for Parasitology 2005 35 6 627 636 (Pubitemid 40603400)
24. Pavithra S. R., Kumar R., Tatu U., Systems analysis of chaperone networks in the malarial parasite Plasmodium falciparum PLoS Computational Biology 2007 3 9 1701 1715 (Pubitemid 47502975)
25. Kumar R., Musiyenko A., Barik S., The heat shock protein 90 of Plasmodium falciparum and antimalarial activity of its inhibitor, geldanamycin Malaria Journal 2003 2 1, article 30
26. Banumathy G., Singh V., Pavithra S. R., Tatu U., Heat shock protein 90 function is essential for Plasmodium falciparum growth in human erythrocytes Journal of Biological Chemistry 2003 278 20 18336 18345 (Pubitemid 36799454)
27. Townson S., Ramirez B., Fakorede F., Mouries M. A., Nwaka S., Challenges in drug discovery for novel antifilarials Expert Opinion on Drug Discovery 2007 2 1 S63 S73
28. Kron M., Yousif F., Ramirez B., Capacity building in anthelmintic drug discovery Expert Opinion on Drug Discovery 2007 2 1 S75 S82
29. Wasan K. M., Brocks D. R., Lee S. D., Sachs-Barrable K., Thornton S. J., Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery Nature Reviews Drug Discovery 2008 7 1 84 99
30. Ramirez B., Bickle Q., Yousif F., Fakorede F., Mouries M. A., Nwaka S., Schistosomes: challenges in compound screening Expert Opinion on Drug Discovery 2007 2 1 S53 S61
31. Saenger I., Laemmler G., Kimmig P., Filarial infections of Mastomys natalensis and their relevance for experimental chemotherapy Acta Tropica 1981 38 3 277 288 (Pubitemid 12238549)
32. Kinnamon K. E., Engle R. R., Poon B. T., Ellis W. Y., McCall J. W., Dzimianski M. T., Anticancer agents suppressive for adult parasites of filariasis in mongolian jirds Experimental Biology and Medicine 2000 224 1 45 49 (Pubitemid 30230418)
33. Pica-Mattoccia L., Doenhoff M. J., Valle C., Basso A., Troiani A. R., Liberti P., Festucci A., Guidi A., Cioli D., Genetic analysis of decreased praziquantel sensitivity in a laboratory strain of Schistosoma mansoni Acta Tropica 2009 111 1 82 85
34. Taldone T., Gillan V., Sun W., Rodina A., Patel P., Maitland K., O'Neill K., Chiosis G., Devaney E., Assay strategies for the discovery and validation of therapeutics targeting Brugia pahangi Hsp90 PLoS Neglected Tropical Diseases 2010 4 6, article e714
35. Sydor J. R., Normant E., Pien C. S., Porter J. R., Ge J., Grenier L., Pak R. H., Ali J. A., Dembski M. S., Hudak J., Patterson J., Penders C., Pink M., Read M. A., Sang J., Woodward C., Zhang Y., Grayzel D. S., Wright J., Barrett J. A., Palombella V. J., Adams J., Tong J. K., Development of 17-allylamino-17- demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90 Proceedings of the National Academy of Sciences of the United States of America 2006 103 46 17408 17413 (Pubitemid 44788982)
36. Sti C., Nagy E., Giricz Z., Vgh L., Csermely P., Ferdinandy P., Heat shock proteins as emerging therapeutic targets British Journal of Pharmacology 2005 146 6 769 780 (Pubitemid 41622243)